NASDAQ:TRVN - Trevena Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Trevena Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $0.97 +0.07 (+7.75 %) (As of 01/26/2020 06:33 AM ET) Add Compare Today's Range$0.91Now: $0.97▼$0.9950-Day Range$0.70MA: $0.81▼$0.9752-Week Range$0.52Now: $0.97▼$2.00Volume1.87 million shsAverage Volume569,335 shsMarket Capitalization$90.15 millionP/E RatioN/ADividend YieldN/ABeta2.61 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Trevena, Inc, a biopharmaceutical company, focuses on the development and commercialization of treatment options that target and treat diseases affecting the central nervous system. Its product candidates include Oliceridine injection, a G protein biased mu-opioid receptor (MOR) ligand that has completed Phase III clinical trials for the management of moderate-to-severe acute pain where intravenous administration is warranted; TRV250, a G protein biased delta- opioid receptor ligand, which is in Phase I clinical study for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR that has completed Phase I clinical study for the treatment of moderate-to-severe acute and chronic pain; TRV027 for the treatment of acute heart failure; and TRV045, a novel S1P modulator for managing chronic pain. Read More… Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:TRVN Previous Symbol CUSIPN/A CIK1429560 Webhttp://www.trevena.com/ Phone610-354-8840Debt Debt-to-Equity Ratio0.23 Current Ratio3.31 Quick Ratio3.31Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$5.73 million Price / Sales15.73 Cash FlowN/A Price / Cash FlowN/A Book Value$0.50 per share Price / Book1.95Profitability EPS (Most Recent Fiscal Year)($0.42) Net Income$-30,780,000.00 Net MarginsN/A Return on Equity-64.05% Return on Assets-40.52%Miscellaneous Employees29 Outstanding Shares92,590,000Market Cap$90.15 million Next Earnings Date3/11/2020 (Estimated) OptionableOptionable Receive TRVN News and Ratings via Email Sign-up to receive the latest news and ratings for TRVN and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:TRVN Rates by TradingView Trevena (NASDAQ:TRVN) Frequently Asked Questions What is Trevena's stock symbol? Trevena trades on the NASDAQ under the ticker symbol "TRVN." How were Trevena's earnings last quarter? Trevena Inc (NASDAQ:TRVN) released its quarterly earnings results on Monday, November, 4th. The biopharmaceutical company reported ($0.09) earnings per share for the quarter, missing analysts' consensus estimates of ($0.08) by $0.02. View Trevena's Earnings History. When is Trevena's next earnings date? Trevena is scheduled to release their next quarterly earnings announcement on Wednesday, March 11th 2020. View Earnings Estimates for Trevena. What price target have analysts set for TRVN? 1 brokers have issued 1 year price objectives for Trevena's stock. Their forecasts range from $3.50 to $3.50. On average, they anticipate Trevena's stock price to reach $3.50 in the next year. This suggests a possible upside of 259.5% from the stock's current price. View Analyst Price Targets for Trevena. What is the consensus analysts' recommendation for Trevena? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Trevena in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Trevena. What are Wall Street analysts saying about Trevena stock? Here are some recent quotes from research analysts about Trevena stock: 1. According to Zacks Investment Research, "Trevena, Inc. is a biopharmaceutical company. It focuses on discovering and developing therapeutics for G protein coupled receptors. The Company's product pipeline includes TRV027, TRV130, TRV734 and Delta opioid biased ligand which are in different clinical phases. Trevena, Inc. is based in King of Prussia, Pennsylvania. " (12/18/2019) 2. HC Wainwright analysts commented, "Our $3.50 price target for Trevena is based on our sum-of-the-parts NPV valuation based on each of the company’s pipeline assets. Our DCF model utilizes a discount rate of 11.5% based on the company’s WACC (Beta of 1.5, equity risk premium of 6.7%). We adjust each indication for probability of success with 3 program has been successful, and we’re confident on the outcome of the cardiac safety study; TRV-250 at 15%; and TRV-045 at 7%. We don’t include TRV-734 in our valuation for the time being, although would look to add it to our valuation model as we gain additional insight. We apply terminal decline rates of 10% for each asset. We assume a 24% tax rate." (5/31/2019) Has Trevena been receiving favorable news coverage? Press coverage about TRVN stock has trended extremely negative on Sunday, InfoTrie Sentiment reports. The research firm identifies negative and positive media coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Trevena earned a coverage optimism score of -4.5 on InfoTrie's scale. They also gave news stories about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the company's share price in the immediate future. View News Stories for Trevena. Are investors shorting Trevena? Trevena saw a decline in short interest in December. As of December 13th, there was short interest totalling 4,420,000 shares, a decline of 14.2% from the November 28th total of 5,150,000 shares. Based on an average trading volume of 512,800 shares, the days-to-cover ratio is currently 8.6 days. Currently, 5.3% of the company's shares are sold short. View Trevena's Current Options Chain. Who are some of Trevena's key competitors? Some companies that are related to Trevena include INDIVIOR PLC/S (INVVY), Minerva Neurosciences (NERV), Spectrum Pharmaceuticals (SPPI), Kalvista Pharmaceuticals (KALV), BioXcel Therapeutics (BTAI), Galera Therapeutics (GRTX), Concert Pharmaceuticals (CNCE), Albireo Pharma (ALBO), Avadel Pharmaceuticals (AVDL), IVERIC bio (ISEE), Geron (GERN), MediciNova (MNOV), Kamada (KMDA), Neptune Wellness Solutions (NEPT) and Wave Life Sciences (WVE). What other stocks do shareholders of Trevena own? Based on aggregate information from My MarketBeat watchlists, some companies that other Trevena investors own include Conatus Pharmaceuticals (CNAT), Novavax (NVAX), Cara Therapeutics (CARA), Synergy Pharmaceuticals (SGYP), TG Therapeutics (TGTX), SCYNEXIS (SCYX), Alibaba Group (BABA), Sorrento Therapeutics (SRNE), Adamis Pharmaceuticals (ADMP) and Egalet (EGLT). Who are Trevena's key executives? Trevena's management team includes the folowing people: Ms. Carrie L. Bourdow, Pres, CEO & Director (Age 56)Dr. Howard A. Rockman M.D., Scientific Founder, Consultant and Member of Scientific Advisory BoardMr. John P. Hamill, VP of Fin. (Age 55)Erin Clark, Sr. Director of Corp. Strategy & Investor RelationsMr. Michael Catalano, VP of Marketing Who are Trevena's major shareholders? Trevena's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Summit X LLC (0.06%). Company insiders that own Trevena stock include John P Hamill, Leon O Moulder Jr, Maxine Gowen and Yacoub Habib. View Institutional Ownership Trends for Trevena. Which institutional investors are buying Trevena stock? TRVN stock was acquired by a variety of institutional investors in the last quarter, including Summit X LLC. Company insiders that have bought Trevena stock in the last two years include John P Hamill, Leon O Moulder Jr and Maxine Gowen. View Insider Buying and Selling for Trevena. How do I buy shares of Trevena? Shares of TRVN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is Trevena's stock price today? One share of TRVN stock can currently be purchased for approximately $0.97. How big of a company is Trevena? Trevena has a market capitalization of $90.15 million and generates $5.73 million in revenue each year. The biopharmaceutical company earns $-30,780,000.00 in net income (profit) each year or ($0.42) on an earnings per share basis. Trevena employs 29 workers across the globe.View Additional Information About Trevena. What is Trevena's official website? The official website for Trevena is http://www.trevena.com/. How can I contact Trevena? Trevena's mailing address is 955 Chesterbrook Boulevard Suite 110, Chesterbrook PA, 19087. The biopharmaceutical company can be reached via phone at 610-354-8840 or via email at [email protected] MarketBeat Community Rating for Trevena (NASDAQ TRVN)Community Ranking: 3.4 out of 5 ( )Outperform Votes: 561 (Vote Outperform)Underperform Votes: 264 (Vote Underperform)Total Votes: 825MarketBeat's community ratings are surveys of what our community members think about Trevena and other stocks. Vote "Outperform" if you believe TRVN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TRVN will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 1/26/2020 by MarketBeat.com StaffFeatured Article: Asset Allocation, Balancing Your Investments
